Name: Name:Th-302
Brand: AABLOCKS
SKU: AA00GU4A
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA00GU4A

Chemical Name: Th-302

CAS Number: 918633-87-1

Molecular Formula: C9H16Br2N5O4P

Molecular Weight: 449.0362

MDL Number: MFCD22420822

SMILES: BrCCNP(=O)(NCCBr)OCc1cnc(n1C)[N+](=O)[O-]

Properties

Complexity: 374

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 21

Hydrogen Bond Acceptor Count: 7

Hydrogen Bond Donor Count: 2

Isotope Atom Count: 0

Rotatable Bond Count: 9

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 0.6

Downstream Synthesis Route

141025-16-3

39070-14-9

N,N’-bis(2-bromoethyl)phosphorodiamidicacid(1-methyl-2-nitro-1H-imidazol-5-yl)methylester

[1]JournalofMedicinalChemistry,2008,vol.51,p.2412-2420

[2]Patent:WO2016/11195,2016,A1.Locationinpatent:Paragraph0053;0103

39070-13-8

918633-87-1

[1]CurrentPatentAssignee:IMMUNOGENESISINC-WO2016/11195,2016,A1

C4H10Br2ClN2OP

39070-14-9

N,N’-bis(2-bromoethyl)phosphorodiamidicacid(1-methyl-2-nitro-1H-imidazol-5-yl)methylester

[1]ACSMedicinalChemistryLetters,2017,vol.8,p.1269-1274

2576-47-8

39070-14-9

N,N’-bis(2-bromoethyl)phosphorodiamidicacid(1-methyl-2-nitro-1H-imidazol-5-yl)methylester

[1]Patent:CN110746459,2020,A.Locationinpatent:Paragraph0039;0056-0061

Literature fold

Title: Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20150501

Title: Metabolism and excretion of TH-302 in dogs.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20120701

Title: TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Journal: Cancer chemotherapy and pharmacology20120601

Title: Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20120401

Title: Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Journal: Cancer chemotherapy and pharmacology20120301

Title: Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Journal: Molecular cancer therapeutics20120301

Title: Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20120201

Title: Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110501

Title: Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Journal: Blood20100902

Title: Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.

Journal: Biological trace element research20100901

Title: Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Journal: Journal of medicinal chemistry20080424

Title: Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422.

Title: Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289.

Title: Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment 8FHX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92.

918633-87-1 | Th-302